<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3068">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439074</url>
  </required_header>
  <id_info>
    <org_study_id>PUMA 418</org_study_id>
    <nct_id>NCT01439074</nct_id>
  </id_info>
  <brief_title>An Open, Randomized, Multi-centre Investigation With Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries.</brief_title>
  <official_title>An Open, Randomized, Comparative, Multi-centre Investigation Evaluating the Efficacy and Tolerance of Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to compare time to healing using absorbent foam silver dressing (Mepilex Ag)
      compared to a silver sulfadiazine (SSD) 1% cream in the treatment of partial thickness burn
      injuries.284 in-patients in 8-12 centres in China will be evaluated. Treatment period will
      be up to 4 weeks with either Mepilex Ag or SSD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Healing</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Burn Epithelised/Healed</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Healing will be defined as 95% or more epithelialisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Dressing Changes</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Including first assembly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Study Burn Healed After One Week</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Burn Injuries</condition>
  <arm_group>
    <arm_group_label>Mepilex Ag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSD Ag cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Silver Sulphadiazine Ag cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepilex Ag</intervention_name>
    <description>Dressing</description>
    <arm_group_label>Mepilex Ag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silver sulphadiazine</intervention_name>
    <description>Cream</description>
    <arm_group_label>SSD Ag cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a deep partial-thickness burn injury covering 2.5%-25% TBSA (3rd degree
             areas not to exceed 10% TBSA)

          -  Burn of thermal origin

          -  Both gender with an age ≥5 years and ≤65 years at ICF

          -  Understood and signed informed consent

          -  Subjects who are younger than the legal consenting age must have a legally authorized
             representative

        One study burn should be chosen which fulfil the following criteria;

          1. isolated burn area (not head and/or face)

          2. 2nd degree deep partial

          3. area is from 1 to 10% BSA

        All deep 2nd degree burn should be treated with the investigation product, Mepilex Ag/SSD
        (according to the randomization).

        Exclusion Criteria:

          -  Burns &quot;occurred&quot; equal to or older than 36 hours

          -  Burns of chemical and electrical origin

          -  Clinically infected burn (as judged by the investigator)

          -  Subjects with lung injury or subjects being on a ventilator

          -  Treatment of the burn with an active agent before study entry. SSD is allowed up to
             24 hours prior to randomization

          -  Subjects with dermatologic skin disorders or necrotizing processes

          -  Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer and severe anaemia) judged by
             the investigator to be a potential interference in the treatment

          -  Subjects with insulin dependent diabetes mellitus

          -  Subjects treated with systemic glucocorticosteroids, except Subjects taking
             occasional doses or doses less than 10mg prednisolon (day or equivalent

          -  Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days

          -  Known allergy/hypersensitivity to any of the components (SSD , Ag glycerin,
             monostearate, glycerol, cetearyl alcohol, leveling agent O, albolene, light liquid
             paraffin, ethylparaben/ silicone, polyurethane foam pad containing a silver compound,
             activated carbon)of the investigation products

          -  Subjects with physical and/or mental conditions that are not expected to comply with
             the investigation

          -  Participation in other clinical investigation(s) within 1 month prior to start of the
             investigation

          -  Pregnancy (pregnancy test needed if they do not use contraceptive)

          -  Previously randomized to this investigation (PUMA 418
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangzhou red Cross Hospital</name>
      <address>
        <city>Gang Zhou</city>
        <state>Guangdong</state>
        <zip>510220</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of ZhengZhou</name>
      <address>
        <city>Zhenzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Jiangyin Peopl's Hospital, affiliated hospital of Medical College of Southeast University</name>
      <address>
        <city>Jiangyin</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 3rd People's Hospital of Wuxi</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Jishuitan Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>30009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>XiAn</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taiyuan Steel burn centre</name>
      <address>
        <city>XingHuaLing District, Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 2nd affiliated Hospital of KunMing Medical college</name>
      <address>
        <city>XiShan District, Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hoospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>September 26, 2014</lastchanged_date>
  <firstreceived_date>September 21, 2011</firstreceived_date>
  <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn injuries</keyword>
  <keyword>Mepilex Ag</keyword>
  <keyword>SSD Ag</keyword>
  <keyword>Partial thickness</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Silver Sulfadiazine</mesh_term>
    <mesh_term>Sulfadiazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mepilex Ag</title>
          <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
        </group>
        <group group_id="P2">
          <title>SSD Ag Cream</title>
          <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mepilex Ag</title>
          <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
        </group>
        <group group_id="B2">
          <title>SSD Ag Cream</title>
          <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="71"/>
                <measurement group_id="B2" value="82"/>
                <measurement group_id="B3" value="153"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.0" spread="12.3"/>
                <measurement group_id="B2" value="35.4" spread="13.2"/>
                <measurement group_id="B3" value="36.2" spread="12.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="68"/>
                <measurement group_id="B2" value="76"/>
                <measurement group_id="B3" value="144"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="41"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
                <measurement group_id="B2" value="57"/>
                <measurement group_id="B3" value="112"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>China</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="71"/>
                <measurement group_id="B2" value="82"/>
                <measurement group_id="B3" value="153"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Healing</title>
        <description>Number of days</description>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Ag</title>
            <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
          </group>
          <group group_id="O2">
            <title>SSD Ag Cream</title>
            <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Healing</title>
            <description>Number of days</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16" spread="7.27"/>
                  <measurement group_id="O2" value="17" spread="6.39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Burn Epithelised/Healed</title>
        <description>Healing will be defined as 95% or more epithelialisation</description>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Ag</title>
            <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
          </group>
          <group group_id="O2">
            <title>SSD Ag Cream</title>
            <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Burn Epithelised/Healed</title>
            <description>Healing will be defined as 95% or more epithelialisation</description>
            <units>percentage of study burn healed</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="87.1" spread="29"/>
                  <measurement group_id="O2" value="85.2" spread="27.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Dressing Changes</title>
        <description>Including first assembly</description>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Ag</title>
            <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
          </group>
          <group group_id="O2">
            <title>SSD Ag Cream</title>
            <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Dressing Changes</title>
            <description>Including first assembly</description>
            <units>applications</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.1" spread="1.86"/>
                  <measurement group_id="O2" value="14.0" spread="13.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Study Burn Healed After One Week</title>
        <time_frame>1 week</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Ag</title>
            <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
          </group>
          <group group_id="O2">
            <title>SSD Ag Cream</title>
            <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>% of Study Burn Healed After One Week</title>
            <units>percentage of study burn healed</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44.3" spread="37.4"/>
                  <measurement group_id="O2" value="27.0" spread="30.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mepilex Ag</title>
          <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
        </group>
        <group group_id="E2">
          <title>SSD Ag Cream</title>
          <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Xia, Zhaofan</name_or_title>
      <organization>Changhai Hospital of Shanghai</organization>
      <phone>+86 2181873471</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
